Comparison of 4-factor PCC reversal of apixaban and rivaroxaban versus warfarin for intracranial hemorrhage
Sign Up to like & getrecommendations! Published in 2021 at "Journal of Thrombosis and Thrombolysis"
DOI: 10.1007/s11239-021-02613-1
Abstract: The purpose of this study is to assess efficacy of 4-factor prothrombin complex concentrates (4F-PCC) for direct oral anticoagulant (DOAC)-associated intracranial hemorrhage (ICH) as compared to its use in warfarin-associated ICH. A retrospective cohort study… read more here.
Keywords: reversal; apixaban rivaroxaban; pcc; efficacy ... See more keywords
Real world prescribing practices of apixaban or rivaroxaban lead-in doses for the treatment of venous thromboembolism in hospitalized patients
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Thrombosis and Thrombolysis"
DOI: 10.1007/s11239-022-02641-5
Abstract: The oral factor Xa inhibitors (OFXAi) apixaban and rivaroxaban are increasingly utilized for the treatment of venous thromboembolism (VTE) with recommended initial higher dose 7- and 21-day lead-in regimens, respectively. In patients receiving initial parenteral… read more here.
Keywords: venous thromboembolism; apixaban rivaroxaban; treatment venous; lead group ... See more keywords
Reversal of Apixaban and Rivaroxaban Using Activated Prothrombin Complex Concentrates in Patients with Major Bleeding
Sign Up to like & getrecommendations! Published in 2019 at "American Journal of Cardiovascular Drugs"
DOI: 10.1007/s40256-019-00383-z
Abstract: Background Clinical experience with using activated prothrombin complex concentrates (aPCCs) to reverse the effects of factor Xa inhibitors is limited. Objectives Our objective was to assess the achievement of effective clinical hemostasis using aPCC in… read more here.
Keywords: apixaban rivaroxaban; major bleeding; activated prothrombin; hemostasis ... See more keywords
Apixaban and rivaroxaban in obese patients treated for venous thromboembolism: Drug levels and clinical outcomes.
Sign Up to like & getrecommendations! Published in 2021 at "Thrombosis research"
DOI: 10.1016/j.thromres.2021.10.009
Abstract: BACKGROUND Direct oral anticoagulants (DOAC) use remains challenging in obese patients treated for Venous-Thrombo-Embolism (VTE) due to the paucity of prospective and dedicated studies. OBJECTIVE To assess rivaroxaban and apixaban concentrations at different time-points after… read more here.
Keywords: apixaban rivaroxaban; patients treated; treated venous; therapy ranges ... See more keywords
Serum or Plasma for Quantification of Direct Oral Anticoagulants?
Sign Up to like & getrecommendations! Published in 2022 at "Therapeutic drug monitoring"
DOI: 10.1097/ftd.0000000000000956
Abstract: BACKGROUND Direct oral anticoagulants (DOACs) are increasingly replacing vitamin K antagonists for prevention of stroke in patients with atrial fibrillation, partly owing to the lack of a need for routine monitoring. Therapeutic drug monitoring may… read more here.
Keywords: serum plasma; serum; apixaban rivaroxaban; factor ... See more keywords
Efficacy and Safety of Direct Oral Factor Xa Inhibitors in 795 Morbidly Obese Patients
Sign Up to like & getrecommendations! Published in 2018 at "Blood"
DOI: 10.1182/blood-2018-99-116396
Abstract: Background: Studies of acute venous thromboembolism (VTE) and non-valvular atrial fibrillation (AF) have shown comparable therapeutic efficacy and similar or lower bleeding risk for direct oral anticoagulants (DOACs) compared to warfarin. Because the representation of… read more here.
Keywords: vte; morbidly obese; apixaban rivaroxaban; efficacy safety ... See more keywords
Variation in Plasma Levels of Apixaban and Rivaroxaban in Clinical Routine Treatment of Venous Thromboembolism
Sign Up to like & getrecommendations! Published in 2022 at "Life"
DOI: 10.3390/life12050705
Abstract: Direct oral anticoagulants (DOACs) apixaban and rivaroxaban are broadly used in the management of venous thromboembolism (VTE). Although not routinely required, measurement of their plasma concentration is advised for an increasing number of indications. Due… read more here.
Keywords: apixaban rivaroxaban; plasma levels; variation; venous thromboembolism ... See more keywords